Market research
DCTH Delcath Systems Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 489M
- P/E ratio
- 1408.0
- Analyst target
- 24
- Dividend yield
- Not available
- Beta
- 0.6
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 489M
- P/E ratio
- 1408.0
- Analyst target
- 24
- Dividend yield
- Not available
- Beta
- 0.6
About
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Research context
Delcath Systems Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DCTH discussion.
5 years, 6 months ago
Delcath Systems, Inc is currently in a long term downtrend where the price is trading 14.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.9.
Delcath Systems, Inc's total revenue sank by 96.7% to $17K since the same quarter in the previous year.
Its net income has dropped by 100.1% to $-7K since the same quarter in the previous year.
Finally, its free cash flow grew by 13.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Delcath Systems, Inc gets an overall score of 2/5.